dpp-4_inhibitors DPP-4 Inhibitors Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)

That signal is preclinical only : Dihexa has never entered a human clinical trial, several of the foundational mechanism papers were retracted in 2025 for falsified/fabricated data [4] , and everything below reflects animal reference data and community conventions provided strictly for research and educational reference not medical advice or a recommendation to self-administer
Recommendations: For best results, take calcium (including milk products) and iron one to two hours apart
Cc yu t gy p lc cho gan v cch glutathione c th tng tc Hng ngy, gan phi i mt vi nhiu p lc: tiu th ru, thuc men, thc phm ch bin, v thm ch l stress ni sinh nh tng triglyceride